Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

NCT02686008 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study was stopped due to lack of funding.

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Olaparib

Sponsor

Yale University